Intelligence

#Advanced Therapies #Cell and gene therapy #Cell culture #Drug development #Drug discovery

From bench to billions: A guide to facilitating scale-up of adherent cultures for cell and gene therapies

Given the potential of emerging advanced therapies, market demand is likely to continue to grow. Generating the required quantity of cells efficiently becomes even more challenging when the cells of interest are attachment-dependent, such as induced pluripotent stem cells (iPSCs). The choice of cell culture platform will have significant operational… Read More

#Resources

#Biopharmaceuticals #GlobalData #Market reporting #Pharmaceutical industry

Top 20 global biopharma companies report 5.4% growth

The top 20 biopharmaceutical companies have recorded a growth of 5.4% in aggregate market capitalisation – from $3.43 trillion on December 31, 2021 to $3.61 trillion on December 31, 2022.  According to analytics company GlobalData, 11 companies indicated double-digit growth, with four companies – Merck & Co… Read More

#Business & Investment #Editor's Choice #Market Reports #News

#Animal models #Animal testing #Drug discovery #Drug safety #FDA #Regulatory

What does the FDA animal testing legislation mean for drug discovery? 

As of late December 2022, the US Food and Drug Administration (FDA) no longer needs drugs to be tested in animals to receive approval, according to legislation signed by President Joe Biden1 – the Modernization Act 2.0. This news has been shared widely as a landmark moment, especially in the eyes… Read More

#Business & Investment #Exclusive Content #Opinion #Regulatory #Trends & Analysis

#Drug development #Drug discovery #Lab automation #Laboratory #Research services #Technology

Technology in the lab: what’s enabling drug discovery?

This latest eBook sponsored by Analytik Jena features insights and expert opinions on the solutions and technologies that are enabling drug discovery breakthroughs and assisting research and development. Download this exclusive eBook to learn more about: The solutions helping drug discovery breakthroughs get to market faster and more efficiently The… Read More

#DDW eBooks #Intelligence

T cells attack a cancer cell
#Financing #Grey Wolf Therapeutics #Immuno-oncology #Investment #Oncology #T cell activation

$49 million raised to fund original immuno-oncology approach

Grey Wolf Therapeutics has closed an oversubscribed $49 million Series B financing co-led by Pfizer Ventures and Earlybird Venture Capital, with investment from Oxford Science Enterprises, British Patient Capital, Canaan and Andera Partners.   Proceeds will support the continued development of the company’s first-of-its-kind immuno-oncology approaches designed to… Read More

#Business & Investment #News #Start-up Zone

Woman tests blood glucose level
#Atrogi #Clinical trial #Diabetes #Phase I trial #Start-ups #Type 2 diabetes

Start-up hopes novel drug could treat cause of type 2 diabetes

Swedish start-up Atrogi has enrolled the first patient in its Phase Ia/b study of ATR-258, a novel b2adrenoceptor agonist for the treatment of type 2 diabetes and comorbidities.  Conducted in Mannheim, Germany by Clinical Research Services (CRS), the trial is expected to be completed by April 2023… Read More

#News #Start-up Zone

#Drug development #Drug discovery #Life sciences #Lithuania #Start-ups

What Lithuania offers life sciences start-ups

Listen to this article on the DDW Podcast: DDW Editor Reece Armstrong takes a look at Lithuania’s life sciences sector and what it means for start-ups operating in the country. A one to watch, would be my first thoughts when thinking about Lithuania and its start-up sector. After… Read More

#Exclusive Content #Start-up Zone

Gene therapy
#Cell and gene therapy #Gene therapy #Investment #Muscular dystrophy #Seed funding #Start-ups

$5 million raised towards gene therapies for muscular diseases

Myosana Therapeutics has completed a seed funding round totalling over $5 million led by investor John Ballantyne.  The capital will go towards developing Myosana’s gene therapy platform for neuromuscular and cardiac disease, with the goal of identifying the first development candidate for Duchenne muscular dystrophy by 2025. Read More

#Business & Investment #News #Start-up Zone

microRNA
#AI / data analytics / healthtech / informatics #Artificial intelligence (AI) #Funding #Investment #Machine learning #Molecular Biology #RNA #Start-ups

$35 million to advance AI-driven RNA structure platform

Atomic AI, a biotechnology company fusing machine learning with structural biology to unlock RNA drug discovery, launched today with a $35 million Series A round.  The financing was led by Playground Global, with participation from 8VC, Factory HQ, Greylock, NotBoring, AME Cloud Ventures, and renowned angel investors… Read More

#Business & Investment #News #Start-up Zone

#Cell and gene therapy #Cell therapy #Drug development #Drug discovery #Gene therapy #Guide

Exclusive insight into cell and gene therapy

Download this exclusive cell and gene therapy guide to learn about: The successes of cell and gene therapies plus the biggest questions facing the sector Expert views on the challenges and opportunities for cell and gene therapies in 2023 Understanding future road maps of cell and gene therapies Why there… Read More

#DDW eBooks

#AI / data analytics / healthtech / informatics #Clinical trial design #Funding #Psychedelics #Start-ups

What will the 2023 drug discovery landscape look like?

Listen to this article on the DDW podcast: DDW Multimedia Editor Megan Thomas observes the 2023 drug discovery landscape, speaking to industry experts and looking at the foundations of 2022 on which next year will lean. Virtual clinical trials ‘Virtual’ and ‘technology’ are concepts which are readily… Read More

#Exclusive Content #Trends & Analysis

#Clinical trials #Drug development #EU #FDA #Regulatory

Regulatory affairs in 2023: Key trends and changes  

Dr Julie Warner is Vice President of Regulatory Affairs at global drug development consultancy, Boyds. In this article, she provides her expert insights into the key regulatory developments likely to shape the global drug development industry this year.    Implementation of the EU Clinical Trials… Read More

#Business & Investment #Exclusive Content #Opinion #Regulatory #Trends & Analysis

RNA
#Clarivate #HAYA Therapeutics #Immunotherapy #mRNA #RNA #RNA sequencing #Strand Therapeutics

RNA companies to watch over the next 12 months

Following the release of Clarivate’s report ‘RNA Technology Companies to Watch’, DDW’s Diana Spencer speaks to Strand Therapeutics’ Jacob Becraft and HAYA Therapeutics’ Samir Ounzain to find out how this technology could revolutionise disease treatment.  Therapies that act upon or incorporate RNA to fight disease have… Read More

#Exclusive Content #Market Reports

#Cancer research #Drug development #Drug discovery #Guide #Oncology #Precision medicine

Trends in precision medicine: Cancer

This is an extraordinarily exciting time to be involved in precision medicine for cancer. This new whitepaper reviews some of the topics and trends in this emerging research area, including: 3D cultures: Spheroids and organoids Organoids in cancer research Tumour microenvironments Organ-on-a-chip and body-on-a-chip 3D bioprinting… Read More

#Resources

Year change from 2022 to 2023
#Clinical trial #Clinical trial design #Covid-19 #Drug delivery #Drug development #Healthcare

Drug discovery predictions: Analysis and insight 

In January 2022, DDW’s Megan Thomas spoke to decision-makers from the drug discovery industry about their predictions on what 2022 holds for our sector. As we head into 2023, DDW will be publishing a series of reflections on these predictions. Here, Thomas reflects specifically… Read More

#Exclusive Content #Opinion #Trends & Analysis

#Clarivate #Drug development #Drug discovery #Market reporting #Personalised medicine #Pharmaceuticals

15 drugs likely to be clinical game-changers

A new report highlights promising therapeutic developments for HIV, Parkinson’s disease, Crohn’s disease, alopaecia, multiple myeloma and breast cancer on the horizon, with personalised medicines strongly represented.  Analysts Clarivate have identified 15 late-stage experimental treatments that are each forecast to deliver annual sales of more than $1… Read More

#Exclusive Content #Trends & Analysis